{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Bar Chart\n",
    "\n",
    "Bar chart is the bread and butter of data visualization. You can basically meet 90% of data analytics needs with bar chart.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "::::{grid}\n",
    ":gutter: 3\n",
    "\n",
    ":::{grid-item-card} Motivation\n",
    "Often, online examples have 1 final example with 50-line chart-generating code, which can be daunting for begginers. I aim to to display, incremental, line-by-line additions with the corresponding outputs, which is best for learning.\n",
    ":::\n",
    "\n",
    ":::{grid-item-card} Approach\n",
    "Typically, most data visualization experts usually do it for creating \"dashboard\" output, but for me, data visualization is a mechanism to understand data, and often few of the output ends up becoming useful by chance. \n",
    ":::\n",
    "\n",
    "::::\n",
    "\n",
    "The \"iterative\" development is often unintentionally discouraged given today's \"Scrum\" culture - you need to definite your X and Y before you even get to the data. Data analysis, especially on new data, requires a lot of exploration."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Playground Data\n",
    "\n",
    "Polars is my favorite dataframe library. There is an interesting open-source effort in biomedical space called OpenTargets.\n",
    "\n",
    "Downloaded the (tab-separated value) from OpenTargets's `IgA Glomerulonephritis`: https://platform.opentargets.org/disease/EFO_0004194 "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "![Alt text](iga_neph.png)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div><style>\n",
       ".dataframe > thead > tr > th,\n",
       ".dataframe > tbody > tr > td {\n",
       "  text-align: right;\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<small>shape: (5, 12)</small><table border=\"1\" class=\"dataframe\"><thead><tr><th>diseaseId</th><th>diseaseName</th><th>drugId</th><th>drugName</th><th>type</th><th>mechanismOfAction</th><th>actionType</th><th>symbol</th><th>name</th><th>phase</th><th>status</th><th>source</th></tr><tr><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>i64</td><td>str</td><td>str</td></tr></thead><tbody><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL429910&quot;</td><td>&quot;DAPAGLIFLOZIN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Sodium/glucose…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SLC5A2&quot;</td><td>&quot;solute carrier…</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1168&quot;</td><td>&quot;RAMIPRIL&quot;</td><td>&quot;Small molecule…</td><td>&quot;Angiotensin-co…</td><td>&quot;Inhibitor&quot;</td><td>&quot;ACE&quot;</td><td>&quot;angiotensin I …</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1535&quot;</td><td>&quot;HYDROXYCHLOROQ…</td><td>&quot;Small molecule…</td><td>&quot;Toll-like rece…</td><td>&quot;Antagonist&quot;</td><td>&quot;TLR7&quot;</td><td>&quot;toll like rece…</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1639&quot;</td><td>&quot;ALISKIREN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Renin inhibito…</td><td>&quot;Inhibitor&quot;</td><td>&quot;REN&quot;</td><td>&quot;renin&quot;</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594217&quot;</td><td>&quot;CANAGLIFLOZIN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Sodium/glucose…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SLC5A2&quot;</td><td>&quot;solute carrier…</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr></tbody></table></div>"
      ],
      "text/plain": [
       "shape: (5, 12)\n",
       "┌────────────┬────────────┬────────────┬───────────┬───┬───────────┬───────┬───────────┬───────────┐\n",
       "│ diseaseId  ┆ diseaseNam ┆ drugId     ┆ drugName  ┆ … ┆ name      ┆ phase ┆ status    ┆ source    │\n",
       "│ ---        ┆ e          ┆ ---        ┆ ---       ┆   ┆ ---       ┆ ---   ┆ ---       ┆ ---       │\n",
       "│ str        ┆ ---        ┆ str        ┆ str       ┆   ┆ str       ┆ i64   ┆ str       ┆ str       │\n",
       "│            ┆ str        ┆            ┆           ┆   ┆           ┆       ┆           ┆           │\n",
       "╞════════════╪════════════╪════════════╪═══════════╪═══╪═══════════╪═══════╪═══════════╪═══════════╡\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL4299 ┆ DAPAGLIFL ┆ … ┆ solute    ┆ 4     ┆ Not yet   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 10         ┆ OZIN      ┆   ┆ carrier   ┆       ┆ recruitin ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ family 5  ┆       ┆ g         ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ member 2  ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1168 ┆ RAMIPRIL  ┆ … ┆ angiotens ┆ 4     ┆ Not yet   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆           ┆   ┆ in I conv ┆       ┆ recruitin ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ erting    ┆       ┆ g         ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ enzyme    ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1535 ┆ HYDROXYCH ┆ … ┆ toll like ┆ 4     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆ LOROQUINE ┆   ┆ receptor  ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ 7         ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1639 ┆ ALISKIREN ┆ … ┆ renin     ┆ 4     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆           ┆   ┆           ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆           ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL4594 ┆ CANAGLIFL ┆ … ┆ solute    ┆ 4     ┆ Not yet   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 217        ┆ OZIN      ┆   ┆ carrier   ┆       ┆ recruitin ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ family 5  ┆       ┆ g         ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ member 2  ┆       ┆           ┆ ct2/s…    │\n",
       "└────────────┴────────────┴────────────┴───────────┴───┴───────────┴───────┴───────────┴───────────┘"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import polars as pl\n",
    "\n",
    "df = pl.read_csv(\"data/EFO_0004194-known-drugs.tsv\", separator=\"\\t\")\n",
    "df.head(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data Viz as exploratory data analysis"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "\n",
    "## Preview the data\n",
    "\n",
    "For starters, an easy way to explore complex datasets like this is to explore seemingly obvious ones.\n",
    "\n",
    "The data contains:\n",
    "- row-by-row information for disease IgA glomerulonephritis (IgA nephropathy)\n",
    "\n",
    "## Base Bar Chart\n",
    "\n",
    "`status` column is relatively understandable, even if you don't come from biomedical background.\n",
    "\n",
    "Let's start with plotting a count of different `status` counts.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-173cc9c5e9bb41c89f53669b372d50c7.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-173cc9c5e9bb41c89f53669b372d50c7.vega-embed details,\n",
       "  #altair-viz-173cc9c5e9bb41c89f53669b372d50c7.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-173cc9c5e9bb41c89f53669b372d50c7\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-173cc9c5e9bb41c89f53669b372d50c7\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-173cc9c5e9bb41c89f53669b372d50c7\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=\"distinct(drugId):Q\",\n",
    "        y=alt.X(\"status:N\")\n",
    "    )\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Adding a Tooltip"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-bad07a8f8ae6487892fb053b21ba78f8.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-bad07a8f8ae6487892fb053b21ba78f8.vega-embed details,\n",
       "  #altair-viz-bad07a8f8ae6487892fb053b21ba78f8.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-bad07a8f8ae6487892fb053b21ba78f8\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-bad07a8f8ae6487892fb053b21ba78f8\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-bad07a8f8ae6487892fb053b21ba78f8\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"status\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=\"distinct(drugId):Q\",\n",
    "        y=alt.Y(\"status:N\"),\n",
    "        tooltip=[\n",
    "            \"distinct(drugId):Q\", \n",
    "            \"status:N\"\n",
    "        ]\n",
    "    )\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Reorder Y-axis (status) by x-axis (count)\n",
    "\n",
    "Altair syntax allows you to sort by another field. In our case, we want to sort by the data result mapped to \"x\" (which is `distinct(drugId)`) but in descending order.\n",
    "\n",
    "When you start to add in more complex encodings and parameters, you have to start using Altair's object representations such as `alt.X()` or `alt.Color()` rather than the column names themselves (this is a shortcut to an extent)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-6d329291447f4b119c4fa02432cfa49c.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-6d329291447f4b119c4fa02432cfa49c.vega-embed details,\n",
       "  #altair-viz-6d329291447f4b119c4fa02432cfa49c.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-6d329291447f4b119c4fa02432cfa49c\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-6d329291447f4b119c4fa02432cfa49c\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-6d329291447f4b119c4fa02432cfa49c\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"status\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"sort\": \"-x\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=\"distinct(drugId):Q\",\n",
    "        y=alt.Y(\"status:N\").sort(\"-x\"),\n",
    "        tooltip=[\n",
    "            \"distinct(drugId):Q\", \n",
    "            \"status:N\"\n",
    "        ]\n",
    "    )\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Add Color encoding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7.vega-embed details,\n",
       "  #altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-23f9dc0e048c45d5b7060a0e1e5c3ad7\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"color\": {\"field\": \"status\", \"type\": \"nominal\"}, \"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"status\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"sort\": \"-x\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=\"distinct(drugId):Q\",\n",
    "        y=alt.Y(\"status:N\").sort(\"-x\"),\n",
    "        color=alt.Color(\"status:N\"),\n",
    "        tooltip=[\n",
    "            \"distinct(drugId):Q\", \n",
    "            \"status:N\"\n",
    "        ]\n",
    "    )\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Remove Unnecesary Titles\n",
    "\n",
    "Many times, I find titles unnecessary or not-presentation ready. \n",
    "\n",
    "For such cases, it's very easy to modify encoding channel titles (e.g. axis titles, legend titles) in Altair.\n",
    "\n",
    "Use `.title()` after each encoding definition."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-9a50c0fc8e764af485e7b2497a51ccfb.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-9a50c0fc8e764af485e7b2497a51ccfb.vega-embed details,\n",
       "  #altair-viz-9a50c0fc8e764af485e7b2497a51ccfb.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-9a50c0fc8e764af485e7b2497a51ccfb\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-9a50c0fc8e764af485e7b2497a51ccfb\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-9a50c0fc8e764af485e7b2497a51ccfb\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"color\": {\"field\": \"status\", \"title\": null, \"type\": \"nominal\"}, \"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"status\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"title\": \"Unique Drugs\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"sort\": \"-x\", \"title\": \"Status\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=alt.X(\"distinct(drugId):Q\").title(\"Unique Drugs\"),\n",
    "        y=alt.Y(\"status:N\").sort(\"-x\").title(\"Status\"),\n",
    "        color=alt.Color(\"status:N\").title(None),\n",
    "        tooltip=[\n",
    "            \"distinct(drugId):Q\", \n",
    "            \"status:N\"\n",
    "        ]\n",
    "    )\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc.vega-embed details,\n",
       "  #altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-0dc9a3fca0d540c68d38c89e10f26dbc\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"color\": {\"field\": \"status\", \"title\": null, \"type\": \"nominal\"}, \"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"status\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"title\": \"Unique Drugs\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"status\", \"sort\": \"-x\", \"title\": \"Status\", \"type\": \"nominal\"}}, \"title\": \"Drug Trials for IgA Nephropathy\", \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import altair as alt\n",
    "\n",
    "fig = (\n",
    "    alt.Chart(df).mark_bar().encode(\n",
    "        x=alt.X(\"distinct(drugId):Q\").title(\"Unique Drugs\"),\n",
    "        y=alt.Y(\"status:N\").sort(\"-x\").title(\"Status\"),\n",
    "        color=alt.Color(\"status:N\").title(None),\n",
    "        tooltip=[\n",
    "            \"distinct(drugId):Q\", \n",
    "            \"status:N\"\n",
    "        ]\n",
    "    )\n",
    ").properties(\n",
    "    title=\"Drug Trials for IgA Nephropathy\",\n",
    ")\n",
    "\n",
    "fig"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<style>\n",
       "  #altair-viz-5ccc196668c5468491341d2c188fd97d.vega-embed {\n",
       "    width: 100%;\n",
       "    display: flex;\n",
       "  }\n",
       "\n",
       "  #altair-viz-5ccc196668c5468491341d2c188fd97d.vega-embed details,\n",
       "  #altair-viz-5ccc196668c5468491341d2c188fd97d.vega-embed details summary {\n",
       "    position: relative;\n",
       "  }\n",
       "</style>\n",
       "<div id=\"altair-viz-5ccc196668c5468491341d2c188fd97d\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-5ccc196668c5468491341d2c188fd97d\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-5ccc196668c5468491341d2c188fd97d\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm/vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm/vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm/vega-lite@5.15.1?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm/vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"5.15.1\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 300, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-d8b010d8a623bfd2a3ba7a368b00fc84\"}, \"mark\": {\"type\": \"bar\"}, \"encoding\": {\"tooltip\": [{\"aggregate\": \"distinct\", \"field\": \"drugId\", \"type\": \"quantitative\"}, {\"field\": \"mechanismOfAction\", \"type\": \"nominal\"}], \"x\": {\"aggregate\": \"distinct\", \"field\": \"drugId\", \"title\": \"Unique Drugs\", \"type\": \"quantitative\"}, \"y\": {\"field\": \"mechanismOfAction\", \"sort\": \"-x\", \"title\": \"Status\", \"type\": \"nominal\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v5.15.1.json\", \"datasets\": {\"data-d8b010d8a623bfd2a3ba7a368b00fc84\": [{\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL429910\", \"drugName\": \"DAPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00922311\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594217\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL608\", \"drugName\": \"PROBUCOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"ATP-binding cassette sub-family A member 1 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ABCA1\", \"name\": \"ATP binding cassette subfamily A member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02231125\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01758120\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 9 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR9\", \"name\": \"toll like receptor 9\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02351752\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04525729\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1069\", \"drugName\": \"VALSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00367562,https://clinicaltrials.gov/ct2/show/NCT00426348\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03218852\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02981212\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02571842\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1690\", \"drugName\": \"HYDROXYCHLOROQUINE SULFATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1237\", \"drugName\": \"LISINOPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1535\", \"drugName\": \"HYDROXYCHLOROQUINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Toll-like receptor 7 antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"TLR7\", \"name\": \"toll like receptor 7\", \"phase\": 4, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02765594\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201576\", \"drugName\": \"RITUXIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"B-lymphocyte antigen CD20 binding agent\", \"actionType\": \"Binding agent\", \"symbol\": \"MS4A1\", \"name\": \"membrane spanning 4-domains A1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00498368\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00863252\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2048484\", \"drugName\": \"CANAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107830\", \"drugName\": \"EMPAGLIFLOZIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Sodium/glucose cotransporter 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SLC5A2\", \"name\": \"solute carrier family 5 member 2\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 4, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04662723\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1168\", \"drugName\": \"RAMIPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01115426\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL846\", \"drugName\": \"CALCITRIOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00319761\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 4, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00755859\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1639\", \"drugName\": \"ALISKIREN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Renin inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"REN\", \"name\": \"renin\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00870493\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03357653\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL9194\", \"drugName\": \"ATRASENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04573478\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4298195\", \"drugName\": \"NARSOPLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Mannan-binding lectin serine protease 2 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"MASP2\", \"name\": \"MBL associated serine protease 2\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03608033\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04578834,https://clinicaltrials.gov/ct2/show/NCT04557462\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201081\", \"drugName\": \"METHYLPREDNISOLONE SODIUM SUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Not yet recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05510323\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02052219\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01392833,https://clinicaltrials.gov/ct2/show/NCT00657059,https://clinicaltrials.gov/ct2/show/NCT00554502\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1513\", \"drugName\": \"IRBESARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1201265\", \"drugName\": \"METHYLPREDNISOLONE HEMISUCCINATE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00657059\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Endothelin receptor ET-A antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"EDNRA\", \"name\": \"endothelin receptor type A\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1542\", \"drugName\": \"AZATHIOPRINE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Amidophosphoribosyltransferase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"PPAT\", \"name\": \"phosphoribosyl pyrophosphate amidotransferase\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00554502,https://clinicaltrials.gov/ct2/show/NCT01392833\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL191\", \"drugName\": \"LOSARTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02232776\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL539423\", \"drugName\": \"SPARSENTAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Type-1 angiotensin II receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"AGTR1\", \"name\": \"angiotensin II receptor type 1\", \"phase\": 3, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03762850\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH1\", \"name\": \"inosine monophosphate dehydrogenase 1\", \"phase\": 3, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00318474\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1200622\", \"drugName\": \"PARICALCITOL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Vitamin D receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"VDR\", \"name\": \"vitamin D receptor\", \"phase\": 3, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00599963\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1456\", \"drugName\": \"MYCOPHENOLATE MOFETIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"IMPDH2\", \"name\": \"inosine monophosphate dehydrogenase 2\", \"phase\": 3, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02187900\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL650\", \"drugName\": \"METHYLPREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 3, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04833374\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2107877\", \"drugName\": \"BLISIBIMOD\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02062684\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13B\", \"name\": \"TNF superfamily member 13b\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594448\", \"drugName\": \"IPTACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Complement factor B inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CFB\", \"name\": \"complement factor B\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03373461\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL635\", \"drugName\": \"PREDNISONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00004448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02808429\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL393220\", \"drugName\": \"ATORVASTATIN CALCIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL131\", \"drugName\": \"PREDNISOLONE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Unknown status\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02662283\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594462\", \"drugName\": \"BATIRAXCEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Growth arrest-specific protein 6 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"GAS6\", \"name\": \"growth arrest specific 6\", \"phase\": 2, \"status\": \"Terminated\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04042623\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL413\", \"drugName\": \"SIROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL269732\", \"drugName\": \"TACROLIMUS\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"FK506-binding protein 1A inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"FKBP1A\", \"name\": \"FKBP prolyl isomerase 1A\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT01224028\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594460\", \"drugName\": \"AT-1501\", \"type\": \"Unknown\", \"mechanismOfAction\": \"CD40 ligand inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD40LG\", \"name\": \"CD40 ligand\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05125068\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1742986\", \"drugName\": \"ATACICEPT\", \"type\": \"Protein\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04716231\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT04287985\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594579\", \"drugName\": \"FELZARTAMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Lymphocyte differentiation antigen CD38 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"CD38\", \"name\": \"CD38 molecule\", \"phase\": 2, \"status\": \"Recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT05065970\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1487\", \"drugName\": \"ATORVASTATIN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"HMG-CoA reductase inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"HMGCR\", \"name\": \"3-hydroxy-3-methylglutaryl-CoA reductase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989871\", \"drugName\": \"AVACOPAN\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"C5a anaphylatoxin chemotactic receptor antagonist\", \"actionType\": \"Antagonist\", \"symbol\": \"C5AR1\", \"name\": \"complement C5a receptor 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02384317\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL1370\", \"drugName\": \"BUDESONIDE\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Glucocorticoid receptor agonist\", \"actionType\": \"Agonist\", \"symbol\": \"NR3C1\", \"name\": \"nuclear receptor subfamily 3 group C member 1\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00767221\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL2103830\", \"drugName\": \"FOSTAMATINIB\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02112838\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL578\", \"drugName\": \"ENALAPRIL\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Angiotensin-converting enzyme inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"ACE\", \"name\": \"angiotensin I converting enzyme\", \"phase\": 2, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT00396721\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL3989516\", \"drugName\": \"FOSTAMATINIB DISODIUM\", \"type\": \"Small molecule\", \"mechanismOfAction\": \"Tyrosine-protein kinase SYK inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"SYK\", \"name\": \"spleen associated tyrosine kinase\", \"phase\": 2, \"status\": \"Withdrawn\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT02433236\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4297722\", \"drugName\": \"CEMDISIRAN\", \"type\": \"Oligonucleotide\", \"mechanismOfAction\": \"Complement C5 mRNA RNAi inhibitor\", \"actionType\": \"Rnai inhibitor\", \"symbol\": \"C5\", \"name\": \"complement C5\", \"phase\": 2, \"status\": \"Active, not recruiting\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03841448\"}, {\"diseaseId\": \"EFO_0004194\", \"diseaseName\": \"IGA glomerulonephritis\", \"drugId\": \"CHEMBL4594614\", \"drugName\": \"SIBEPRENLIMAB\", \"type\": \"Antibody\", \"mechanismOfAction\": \"Tumor necrosis factor ligand superfamily member 13 inhibitor\", \"actionType\": \"Inhibitor\", \"symbol\": \"TNFSF13\", \"name\": \"TNF superfamily member 13\", \"phase\": 1, \"status\": \"Completed\", \"source\": \"https://clinicaltrials.gov/ct2/show/NCT03719443\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.Chart(df).mark_bar().encode(\n",
    "    x=alt.X(\"distinct(drugId):Q\").title(\"Unique Drugs\"),\n",
    "    y=alt.Y(\"mechanismOfAction:N\").sort(\"-x\").title(\"Status\"),\n",
    "    tooltip=[\n",
    "        \"distinct(drugId):Q\", \n",
    "        \"mechanismOfAction:N\"\n",
    "    ]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div><style>\n",
       ".dataframe > thead > tr > th,\n",
       ".dataframe > tbody > tr > td {\n",
       "  text-align: right;\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<small>shape: (86, 12)</small><table border=\"1\" class=\"dataframe\"><thead><tr><th>diseaseId</th><th>diseaseName</th><th>drugId</th><th>drugName</th><th>type</th><th>mechanismOfAction</th><th>actionType</th><th>symbol</th><th>name</th><th>phase</th><th>status</th><th>source</th></tr><tr><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>str</td><td>i64</td><td>str</td><td>str</td></tr></thead><tbody><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL429910&quot;</td><td>&quot;DAPAGLIFLOZIN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Sodium/glucose…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SLC5A2&quot;</td><td>&quot;solute carrier…</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1168&quot;</td><td>&quot;RAMIPRIL&quot;</td><td>&quot;Small molecule…</td><td>&quot;Angiotensin-co…</td><td>&quot;Inhibitor&quot;</td><td>&quot;ACE&quot;</td><td>&quot;angiotensin I …</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1535&quot;</td><td>&quot;HYDROXYCHLOROQ…</td><td>&quot;Small molecule…</td><td>&quot;Toll-like rece…</td><td>&quot;Antagonist&quot;</td><td>&quot;TLR7&quot;</td><td>&quot;toll like rece…</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1639&quot;</td><td>&quot;ALISKIREN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Renin inhibito…</td><td>&quot;Inhibitor&quot;</td><td>&quot;REN&quot;</td><td>&quot;renin&quot;</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594217&quot;</td><td>&quot;CANAGLIFLOZIN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Sodium/glucose…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SLC5A2&quot;</td><td>&quot;solute carrier…</td><td>4</td><td>&quot;Not yet recrui…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1535&quot;</td><td>&quot;HYDROXYCHLOROQ…</td><td>&quot;Small molecule…</td><td>&quot;Toll-like rece…</td><td>&quot;Antagonist&quot;</td><td>&quot;TLR9&quot;</td><td>&quot;toll like rece…</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL578&quot;</td><td>&quot;ENALAPRIL&quot;</td><td>&quot;Small molecule…</td><td>&quot;Angiotensin-co…</td><td>&quot;Inhibitor&quot;</td><td>&quot;ACE&quot;</td><td>&quot;angiotensin I …</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1456&quot;</td><td>&quot;MYCOPHENOLATE …</td><td>&quot;Small molecule…</td><td>&quot;Inosine-5&#x27;-mon…</td><td>&quot;Inhibitor&quot;</td><td>&quot;IMPDH1&quot;</td><td>&quot;inosine monoph…</td><td>4</td><td>&quot;Unknown status…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1069&quot;</td><td>&quot;VALSARTAN&quot;</td><td>&quot;Small molecule…</td><td>&quot;Type-1 angiote…</td><td>&quot;Antagonist&quot;</td><td>&quot;AGTR1&quot;</td><td>&quot;angiotensin II…</td><td>4</td><td>&quot;Unknown status…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1690&quot;</td><td>&quot;HYDROXYCHLOROQ…</td><td>&quot;Small molecule…</td><td>&quot;Toll-like rece…</td><td>&quot;Antagonist&quot;</td><td>&quot;TLR7&quot;</td><td>&quot;toll like rece…</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1535&quot;</td><td>&quot;HYDROXYCHLOROQ…</td><td>&quot;Small molecule…</td><td>&quot;Toll-like rece…</td><td>&quot;Antagonist&quot;</td><td>&quot;TLR9&quot;</td><td>&quot;toll like rece…</td><td>4</td><td>&quot;Unknown status…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL608&quot;</td><td>&quot;PROBUCOL&quot;</td><td>&quot;Small molecule…</td><td>&quot;ATP-binding ca…</td><td>&quot;Inhibitor&quot;</td><td>&quot;ABCA1&quot;</td><td>&quot;ATP binding ca…</td><td>4</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td><td>&hellip;</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594460&quot;</td><td>&quot;AT-1501&quot;</td><td>&quot;Unknown&quot;</td><td>&quot;CD40 ligand in…</td><td>&quot;Inhibitor&quot;</td><td>&quot;CD40LG&quot;</td><td>&quot;CD40 ligand&quot;</td><td>2</td><td>&quot;Recruiting&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1742986&quot;</td><td>&quot;ATACICEPT&quot;</td><td>&quot;Protein&quot;</td><td>&quot;Tumor necrosis…</td><td>&quot;Inhibitor&quot;</td><td>&quot;TNFSF13&quot;</td><td>&quot;TNF superfamil…</td><td>2</td><td>&quot;Active, not re…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594614&quot;</td><td>&quot;SIBEPRENLIMAB&quot;</td><td>&quot;Antibody&quot;</td><td>&quot;Tumor necrosis…</td><td>&quot;Inhibitor&quot;</td><td>&quot;TNFSF13&quot;</td><td>&quot;TNF superfamil…</td><td>2</td><td>&quot;Active, not re…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594579&quot;</td><td>&quot;FELZARTAMAB&quot;</td><td>&quot;Antibody&quot;</td><td>&quot;Lymphocyte dif…</td><td>&quot;Inhibitor&quot;</td><td>&quot;CD38&quot;</td><td>&quot;CD38 molecule&quot;</td><td>2</td><td>&quot;Recruiting&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1487&quot;</td><td>&quot;ATORVASTATIN&quot;</td><td>&quot;Small molecule…</td><td>&quot;HMG-CoA reduct…</td><td>&quot;Inhibitor&quot;</td><td>&quot;HMGCR&quot;</td><td>&quot;3-hydroxy-3-me…</td><td>2</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL3989871&quot;</td><td>&quot;AVACOPAN&quot;</td><td>&quot;Small molecule…</td><td>&quot;C5a anaphylato…</td><td>&quot;Antagonist&quot;</td><td>&quot;C5AR1&quot;</td><td>&quot;complement C5a…</td><td>2</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL1370&quot;</td><td>&quot;BUDESONIDE&quot;</td><td>&quot;Small molecule…</td><td>&quot;Glucocorticoid…</td><td>&quot;Agonist&quot;</td><td>&quot;NR3C1&quot;</td><td>&quot;nuclear recept…</td><td>2</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL2103830&quot;</td><td>&quot;FOSTAMATINIB&quot;</td><td>&quot;Small molecule…</td><td>&quot;Tyrosine-prote…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SYK&quot;</td><td>&quot;spleen associa…</td><td>2</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL578&quot;</td><td>&quot;ENALAPRIL&quot;</td><td>&quot;Small molecule…</td><td>&quot;Angiotensin-co…</td><td>&quot;Inhibitor&quot;</td><td>&quot;ACE&quot;</td><td>&quot;angiotensin I …</td><td>2</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL3989516&quot;</td><td>&quot;FOSTAMATINIB D…</td><td>&quot;Small molecule…</td><td>&quot;Tyrosine-prote…</td><td>&quot;Inhibitor&quot;</td><td>&quot;SYK&quot;</td><td>&quot;spleen associa…</td><td>2</td><td>&quot;Withdrawn&quot;</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4297722&quot;</td><td>&quot;CEMDISIRAN&quot;</td><td>&quot;Oligonucleotid…</td><td>&quot;Complement C5 …</td><td>&quot;Rnai inhibitor…</td><td>&quot;C5&quot;</td><td>&quot;complement C5&quot;</td><td>2</td><td>&quot;Active, not re…</td><td>&quot;https://clinic…</td></tr><tr><td>&quot;EFO_0004194&quot;</td><td>&quot;IGA glomerulon…</td><td>&quot;CHEMBL4594614&quot;</td><td>&quot;SIBEPRENLIMAB&quot;</td><td>&quot;Antibody&quot;</td><td>&quot;Tumor necrosis…</td><td>&quot;Inhibitor&quot;</td><td>&quot;TNFSF13&quot;</td><td>&quot;TNF superfamil…</td><td>1</td><td>&quot;Completed&quot;</td><td>&quot;https://clinic…</td></tr></tbody></table></div>"
      ],
      "text/plain": [
       "shape: (86, 12)\n",
       "┌────────────┬────────────┬────────────┬───────────┬───┬───────────┬───────┬───────────┬───────────┐\n",
       "│ diseaseId  ┆ diseaseNam ┆ drugId     ┆ drugName  ┆ … ┆ name      ┆ phase ┆ status    ┆ source    │\n",
       "│ ---        ┆ e          ┆ ---        ┆ ---       ┆   ┆ ---       ┆ ---   ┆ ---       ┆ ---       │\n",
       "│ str        ┆ ---        ┆ str        ┆ str       ┆   ┆ str       ┆ i64   ┆ str       ┆ str       │\n",
       "│            ┆ str        ┆            ┆           ┆   ┆           ┆       ┆           ┆           │\n",
       "╞════════════╪════════════╪════════════╪═══════════╪═══╪═══════════╪═══════╪═══════════╪═══════════╡\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL4299 ┆ DAPAGLIFL ┆ … ┆ solute    ┆ 4     ┆ Not yet   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 10         ┆ OZIN      ┆   ┆ carrier   ┆       ┆ recruitin ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ family 5  ┆       ┆ g         ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ member 2  ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1168 ┆ RAMIPRIL  ┆ … ┆ angiotens ┆ 4     ┆ Not yet   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆           ┆   ┆ in I conv ┆       ┆ recruitin ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ erting    ┆       ┆ g         ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ enzyme    ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1535 ┆ HYDROXYCH ┆ … ┆ toll like ┆ 4     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆ LOROQUINE ┆   ┆ receptor  ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ 7         ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL1639 ┆ ALISKIREN ┆ … ┆ renin     ┆ 4     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆           ┆   ┆           ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆           ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "│ …          ┆ …          ┆ …          ┆ …         ┆ … ┆ …         ┆ …     ┆ …         ┆ …         │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL578  ┆ ENALAPRIL ┆ … ┆ angiotens ┆ 2     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆            ┆           ┆   ┆ in I conv ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ erting    ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ enzyme    ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL3989 ┆ FOSTAMATI ┆ … ┆ spleen    ┆ 2     ┆ Withdrawn ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 516        ┆ NIB       ┆   ┆ associate ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆ DISODIUM  ┆   ┆ d         ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆ tyrosine  ┆       ┆           ┆ ct2/s…    │\n",
       "│            ┆            ┆            ┆           ┆   ┆ kinas…    ┆       ┆           ┆           │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL4297 ┆ CEMDISIRA ┆ … ┆ complemen ┆ 2     ┆ Active,   ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 722        ┆ N         ┆   ┆ t C5      ┆       ┆ not recru ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆           ┆       ┆ iting     ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "│ EFO_000419 ┆ IGA glomer ┆ CHEMBL4594 ┆ SIBEPRENL ┆ … ┆ TNF super ┆ 1     ┆ Completed ┆ https://c │\n",
       "│ 4          ┆ ulonephrit ┆ 614        ┆ IMAB      ┆   ┆ family    ┆       ┆           ┆ linicaltr │\n",
       "│            ┆ is         ┆            ┆           ┆   ┆ member 13 ┆       ┆           ┆ ials.gov/ │\n",
       "│            ┆            ┆            ┆           ┆   ┆           ┆       ┆           ┆ ct2/s…    │\n",
       "└────────────┴────────────┴────────────┴───────────┴───┴───────────┴───────┴───────────┴───────────┘"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "data-expressions-XOHyUNvQ-py3.10",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}